EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that the company’s breakthrough prescription daily eyelid and lash hygiene product, Avenova™, will be marketed in New Zealand through a partnership with Ophthalmic Instrument Company.
Ophthalmic Instrument Company (OIC) is the leading supplier of diagnostic and surgical products to the ophthalmology and optometry sectors in New Zealand.
“This new agreement is part of our strategy to make Avenova available around the world,” said Ron Najafi, Ph.D., President and CEO of NovaBay. “We are already in China, Southeast Asia and the Middle East. Now, patients in New Zealand will be able to get the benefits of this important product.”
Avenova is the only lid & lash product containing Neutrox. Neutrox is NovaBay’s proprietary pure hypochlorous acid without any sodium hypochlorite impurities. Hypochlorous acid is naturally produced by white blood cells to fight microbial invaders. Lab tests show that NovaBay’s proprietary formulation of hypochlorous acid is effective in solution both at killing microbes and at neutralizing the bacterial enzymes and toxins that contribute to common eye conditions like blepharitis, meibomian gland dysfunction and associated dry eye.
Patients and doctors report that a regimen of daily lid hygiene using Avenova has been able to finally bring relief to people suffering from these often-painful conditions.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, cleared by the US FDA as a 510(k) medical device; the NEUTROX™ Family of Products includes AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, and CELLERX™ for the cosmetic surgery and aesthetic dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™ which is in development as a new drug in urology and dermatology.
NovaBay has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (the Ukraine).
In June 2015 NovaBay announced FDA clearance of intelli-Case™, an innovative, easy-to-use device for safely disinfecting soft and rigid gas permeable (RGP) contact lenses with hydrogen peroxide.
Stay informed on NovaBay's progress:
Download
our Mobile InvestorApp from the Apple
Store or Google
Play
Like us on Facebook
Follow
us on Twitter
Connect
with NovaBay on LinkedIn
Join
us on Google+
Visit
NovaBay's
Website
Forward-looking Statements
This press release contains "forward-looking statements." Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
